Eli Lilly and Boehringer Ingelheim’s longstanding alliance in diabetes has delivered another new product, this time a three-drug combination – Trijardy XR – that extends their blockbuster ...

Eli Lilly and Boehringer Ingelheim have changed the terms of ... Although the market for diabetes drugs is fiercely competitive, Jardiance gained a substantial advantage when it became the first ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

In a major setback to Boehringer Ingelheim, the Delhi High Court has upheld the maintainability of a revocation petition ...